ZTS Stock - Zoetis Inc.
Unlock GoAI Insights for ZTS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.26B | $8.54B | $8.08B | $7.78B | $6.67B |
| Gross Profit | $6.40B | $5.83B | $5.48B | $5.31B | $4.46B |
| Gross Margin | 69.1% | 68.3% | 67.8% | 68.3% | 66.8% |
| Operating Income | $3.39B | $3.07B | $2.93B | $2.80B | $2.27B |
| Net Income | $2.49B | $2.34B | $2.11B | $2.04B | $1.64B |
| Net Margin | 26.9% | 27.4% | 26.2% | 26.2% | 24.5% |
| EPS | $5.47 | $5.08 | $4.51 | $4.29 | $3.44 |
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 15th 2025 | BofA Securities | Downgrade | Neutral | $135 |
| December 9th 2025 | Barclays | Initiation | Equal Weight | $136 |
| November 21st 2025 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| July 17th 2025 | Leerink Partners | Downgrade | Market Perform | $155 |
| June 18th 2025 | Stifel | Downgrade | Hold | $160 |
| December 2nd 2024 | Leerink Partners | Initiation | Outperform | $215 |
| July 25th 2024 | BTIG Research | Initiation | Buy | $220 |
| January 12th 2024 | Stifel | Reiterated | Buy | $215← $195 |
| December 19th 2023 | Jefferies | Resumed | Buy | $230 |
| December 7th 2023 | Exane BNP Paribas | Initiation | Outperform | $237 |
| September 6th 2023 | HSBC Securities | Initiation | Buy | $230 |
| July 12th 2022 | Piper Sandler | Initiation | Overweight | $205 |
Earnings History & Surprises
ZTSEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $1.40 | — | — | — |
Q4 2025 | Nov 4, 2025 | $1.62 | $1.70 | +4.9% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $1.62 | $1.76 | +8.6% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $1.41 | $1.48 | +5.0% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $1.37 | $1.40 | +2.2% | ✓ BEAT |
Q4 2024 | Nov 4, 2024 | $1.46 | $1.58 | +8.2% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $1.49 | $1.56 | +4.7% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $1.34 | $1.38 | +3.0% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $1.32 | $1.24 | -6.1% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $1.36 | $1.36 | 0.0% | = MET |
Q3 2023 | Aug 8, 2023 | $1.32 | $1.41 | +6.8% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $1.26 | $1.31 | +4.0% | ✓ BEAT |
Q1 2023 | Feb 14, 2023 | $1.05 | $1.15 | +9.5% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $1.24 | $1.21 | -2.4% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $1.22 | $1.20 | -1.6% | ✗ MISS |
Q2 2022 | May 5, 2022 | $1.23 | $1.32 | +7.3% | ✓ BEAT |
Q1 2022 | Feb 15, 2022 | $0.96 | $1.00 | +4.2% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $1.10 | $1.25 | +13.6% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $1.08 | $1.19 | +10.2% | ✓ BEAT |
Latest News
Zoetis Prices $1.75B 0.25% Convertible Senior Notes Due 2029 Private Offering To Fund $1.6B Share Repurchases And Capped Call Transactions
📈 PositiveZoetis Intends To Offer $1.75B Convertible Senior Notes Due 2029
➖ NeutralZoetis Board Approves 6% Dividend Increase To $0.53/Share
📈 PositiveBarclays Initiates Coverage On Zoetis with Equal-Weight Rating, Announces Price Target of $136
➖ NeutralZoetis Receives Health Canada Approval For Portela
📈 PositiveBTIG Reiterates Buy on Zoetis, Maintains $160 Price Target
📈 PositiveZoetis Gets European Commission Approval For Lenivia For Reduction Of Pain Associated With Osteoarthritis In Dogs
📈 PositiveCNBC Halftime Report Final Trades: Uber Technologies, Humana, Zoetis, Zoom Communications
➖ NeutralZoetis shares are trading higher. Keybanc initiated coverage on the stock with a Sector Weight rating.
➖ NeutralKeybanc Initiates Coverage On Zoetis with Sector Weight Rating
➖ NeutralStifel Maintains Hold on Zoetis, Lowers Price Target to $130
📉 NegativeBTIG Maintains Buy on Zoetis, Lowers Price Target to $160
📈 PositiveZoetis Acquires Veterinary Pathology Group To Strengthen Veterinary Diagnostics In UK And Ireland; No Financial Terms Disclosed
📈 PositiveMorgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $175
➖ NeutralUBS Maintains Neutral on Zoetis, Lowers Price Target to $141
➖ NeutralJP Morgan Maintains Overweight on Zoetis, Lowers Price Target to $200
➖ NeutralZoetis down after guidance cut on macro trends
📉 NegativeZoetis shares are trading lower after the company lowered its FY2025 sales outlook while reaffirming EPS guidance.
📉 NegativeZoetis shares are falling after the company lowered its FY2025 sales outlook while reaffirming EPS guidance.
📉 NegativeZoetis Affirms FY2025 Adj EPS Guidance of $6.30-$6.40 vs $6.35 Est; Lowers FY2025 Sales Guidance from $9.450B-$9.600B to $9.400B-$9.475B vs $9.516B Est
➖ NeutralFrequently Asked Questions about ZTS
What is ZTS's current stock price?
What is the analyst price target for ZTS?
What sector is Zoetis Inc. in?
What is ZTS's market cap?
Does ZTS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ZTS for comparison